Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Bio-Rad Laboratories's operating assets for the quarter that ended in Mar. 2026 was €7,115 Mil. Bio-Rad Laboratories's operating liabilities for the quarter that ended in Mar. 2026 was €1,350 Mil. Bio-Rad Laboratories's Total Assets for the quarter that ended in Dec. 2025 was €9,032 Mil. Therefore, Bio-Rad Laboratories's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.64.
Bio-Rad Laboratories Scaled Net Operating Assets Related Terms
Bio-Rad Laboratories Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Bio-Rad Laboratories's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories Scaled Net Operating Assets Chart
FRA:BUWA vs GKOS, BRKR, PODD: Scaled Net Operating Assets Comparison
For the Medical Devices subindustry, Bio-Rad Laboratories's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Rad Laboratories Scaled Net Operating Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Bio-Rad Laboratories's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.64 mean?
Bio-Rad Laboratories (FRA:BUWA) has a Scaled Net Operating Assets of 0.64 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Bio-Rad Laboratories and its competitors.
Is Bio-Rad Laboratories' Scaled Net Operating Assets too high?
Bio-Rad Laboratories' current Scaled Net Operating Assets is 0.64. Overall, Bio-Rad Laboratories has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' Scaled Net Operating Assets compare to GKOS and BRKR?
Bio-Rad Laboratories' Scaled Net Operating Assets of 0.64 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Bio-Rad Laboratories and its competitors. Bio-Rad Laboratories's current Scaled Net Operating Assets is 0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Fairly Valued. The stock's GF Value™ is €272.77, compared to a current price of €256.60 — trading 5.9% below its estimated fair value. The current Scaled Net Operating Assets is 0.64. Bio-Rad Laboratories' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current Scaled Net Operating Assets is 0.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be undervalued.
The current stock price of €256.60 is trading 5.9% below its estimated GF Value™ of €272.77.
GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.
Key valuation signals for FRA:BUWA:
Scaled Net Operating Assets: 0.64
GF Value™: €272.77 vs. price of €256.60 (5.9% below fair value)
No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
72GF Score
Get the complete analysis for FRA:BUWA
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BUWA has been successfully added to your 
